Loading
Using two HER2 antibodies (trastuzumab and pertuzumab) at once, which works better than one.
Trastuzumab (domain IV) plus pertuzumab (domain II) block ligand-independent and ligand-dependent signalling and enhance ADCC. CLEOPATRA (OS +16 months), NeoSphere (pCR), and APHINITY (node-positive iDFS) established it; Phesgo delivers both subcutaneously. Now being paired with T-DXd (DESTINY-Breast09) and tucatinib (HER2CLIMB-05).
In plain words · A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.
Showing the target this term concerns: HER2.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares APHINITY, Pertuzumab, Trastuzumab.
Shares CLEOPATRA, Trastuzumab, HER2, HER2-positive breast cancer.
Shares CLEOPATRA, Pertuzumab, Trastuzumab, HER2.
Shares Early FDG-PET response → chemotherapy omission (HER2+), Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares APHINITY, HER2 IHC 3+ (HER2-positive by immunohistochemistry), Pertuzumab, Trastuzumab.
Shares Trastuzumab, HER2, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.